GlaxoSmithKline plc (SIX: GSK.SW) Stock Competitors & Peer Comparison

GlaxoSmithKline plc (SIX: GSK.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK.SW stands at 101.6B. In comparison, LLY.SW has a market cap of 891.7B. Regarding current trading prices, GSK.SW is priced at CHF 19.98 on the SIX, while LLY.SW trades at CHF 1,000.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK.SW currently has a P/E ratio of 18.76, whereas LLY.SW's P/E ratio is 39.73. In terms of profitability, GSK.SW's ROE is +0.38%, compared to LLY.SW's ROE of +0.93%. Regarding short-term risk, GSK.SW is not fully comparable compared to LLY.SW. This indicates unavailable risk data in terms of short-term price fluctuations for GSK.SW.Check LLY.SW's competition here

GlaxoSmithKline plc (SIX: GSK.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK.SW stands at 101.6B. In comparison, JNJ.SW has a market cap of 507.8B. Regarding current trading prices, GSK.SW is priced at CHF 19.98 on the SIX, while JNJ.SW trades at CHF 210.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK.SW currently has a P/E ratio of 18.76, whereas JNJ.SW's P/E ratio is 23.97. In terms of profitability, GSK.SW's ROE is +0.38%, compared to JNJ.SW's ROE of +0.26%. Regarding short-term risk, GSK.SW is not fully comparable compared to JNJ.SW. This indicates unavailable risk data in terms of short-term price fluctuations for GSK.SW.Check JNJ.SW's competition here

GlaxoSmithKline plc (SIX: GSK.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK.SW stands at 101.6B. In comparison, ROP.SW has a market cap of 299B. Regarding current trading prices, GSK.SW is priced at CHF 19.98 on the SIX, while ROP.SW trades at CHF 375.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK.SW currently has a P/E ratio of 18.76, whereas ROP.SW's P/E ratio is 19.30. In terms of profitability, GSK.SW's ROE is +0.38%, compared to ROP.SW's ROE of +0.37%. Regarding short-term risk, GSK.SW is not fully comparable compared to ROP.SW. This indicates unavailable risk data in terms of short-term price fluctuations for GSK.SW.Check ROP.SW's competition here

GlaxoSmithKline plc (SIX: GSK.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK.SW stands at 101.6B. In comparison, RO.SW has a market cap of 297.6B. Regarding current trading prices, GSK.SW is priced at CHF 19.98 on the SIX, while RO.SW trades at CHF 379.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK.SW currently has a P/E ratio of 18.76, whereas RO.SW's P/E ratio is 22.76. In terms of profitability, GSK.SW's ROE is +0.38%, compared to RO.SW's ROE of +0.37%. Regarding short-term risk, GSK.SW is not fully comparable compared to RO.SW. This indicates unavailable risk data in terms of short-term price fluctuations for GSK.SW.Check RO.SW's competition here

GlaxoSmithKline plc (SIX: GSK.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK.SW stands at 101.6B. In comparison, ROG.SW has a market cap of 256.6B. Regarding current trading prices, GSK.SW is priced at CHF 19.98 on the SIX, while ROG.SW trades at CHF 322.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK.SW currently has a P/E ratio of 18.76, whereas ROG.SW's P/E ratio is 20.11. In terms of profitability, GSK.SW's ROE is +0.38%, compared to ROG.SW's ROE of +0.41%. Regarding short-term risk, GSK.SW is not fully comparable compared to ROG.SW. This indicates unavailable risk data in terms of short-term price fluctuations for GSK.SW.Check ROG.SW's competition here

GlaxoSmithKline plc (SIX: GSK.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK.SW stands at 101.6B. In comparison, NOVN.SW has a market cap of 242.2B. Regarding current trading prices, GSK.SW is priced at CHF 19.98 on the SIX, while NOVN.SW trades at CHF 127.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK.SW currently has a P/E ratio of 18.76, whereas NOVN.SW's P/E ratio is 18.55. In terms of profitability, GSK.SW's ROE is +0.38%, compared to NOVN.SW's ROE of +0.30%. Regarding short-term risk, GSK.SW is not fully comparable compared to NOVN.SW. This indicates unavailable risk data in terms of short-term price fluctuations for GSK.SW.Check NOVN.SW's competition here

GlaxoSmithKline plc (SIX: GSK.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK.SW stands at 101.6B. In comparison, GILD.SW has a market cap of 143.2B. Regarding current trading prices, GSK.SW is priced at CHF 19.98 on the SIX, while GILD.SW trades at CHF 115.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK.SW currently has a P/E ratio of 18.76, whereas GILD.SW's P/E ratio is 21.45. In terms of profitability, GSK.SW's ROE is +0.38%, compared to GILD.SW's ROE of -0.17%. Regarding short-term risk, GSK.SW is not fully comparable compared to GILD.SW. This indicates unavailable risk data in terms of short-term price fluctuations for GSK.SW.Check GILD.SW's competition here

GlaxoSmithKline plc (SIX: GSK.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK.SW stands at 101.6B. In comparison, BMY.SW has a market cap of 87.7B. Regarding current trading prices, GSK.SW is priced at CHF 19.98 on the SIX, while BMY.SW trades at CHF 52.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK.SW currently has a P/E ratio of 18.76, whereas BMY.SW's P/E ratio is 10.13. In terms of profitability, GSK.SW's ROE is +0.38%, compared to BMY.SW's ROE of +0.45%. Regarding short-term risk, GSK.SW is not fully comparable compared to BMY.SW. This indicates unavailable risk data in terms of short-term price fluctuations for GSK.SW.Check BMY.SW's competition here

GlaxoSmithKline plc (SIX: GSK.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK.SW stands at 101.6B. In comparison, BAYN.SW has a market cap of 44.8B. Regarding current trading prices, GSK.SW is priced at CHF 19.98 on the SIX, while BAYN.SW trades at CHF 45.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK.SW currently has a P/E ratio of 18.76, whereas BAYN.SW's P/E ratio is 10.16. In terms of profitability, GSK.SW's ROE is +0.38%, compared to BAYN.SW's ROE of -0.06%. Regarding short-term risk, GSK.SW is not fully comparable compared to BAYN.SW. This indicates unavailable risk data in terms of short-term price fluctuations for GSK.SW.Check BAYN.SW's competition here

GlaxoSmithKline plc (SIX: GSK.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK.SW stands at 101.6B. In comparison, BIIB.SW has a market cap of 20.8B. Regarding current trading prices, GSK.SW is priced at CHF 19.98 on the SIX, while BIIB.SW trades at CHF 141.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK.SW currently has a P/E ratio of 18.76, whereas BIIB.SW's P/E ratio is 11.19. In terms of profitability, GSK.SW's ROE is +0.38%, compared to BIIB.SW's ROE of +0.05%. Regarding short-term risk, GSK.SW is not fully comparable compared to BIIB.SW. This indicates unavailable risk data in terms of short-term price fluctuations for GSK.SW.Check BIIB.SW's competition here